Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Ella R Thompson, PhD BSc, Tamia Nguyen, Yamuna Kankanige, PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Rachel Thijssen, PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, John F. Seymour, Andrew W Roberts, MBBS, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137411

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136872

Published: 2020

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej

Blood (2019) 134 (Supplement_1): 2791.

https://doi.org/10.1182/blood-2019-122974

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Blood (2019) 134 (Supplement_1): 170.

https://doi.org/10.1182/blood-2019-125488

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): 333.

https://doi.org/10.1182/blood-2018-99-114243

Published: 2018

Journal Articles

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Meaghan Wall, MBBS, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2018-99-113905

Published: 2018

Journal Articles

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Jianan Gong, PhD, Rachel Thijssen, Richard W Birkinshaw, PhD, Ella Thompson, PhD, Charis E Teh, PhD, Tamia Nguyen, Zhen Xu, PhD, Christoffer Flensburg, PhD, Thomas Lew, MBBS, Ian Majewski, PhD, Daniel Gray, David Alan Westerman, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, John F. Seymour, MBBS, PhD, Peter E Czabotar, PhD, David Huang, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): LBA-7.

https://doi.org/10.1182/blood-2018-120761

Published: 2018

Journal Articles

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Donia M Moujalled, PhD, Diane T Hanna, Giovanna Pomilio, Veronique Litalien, Shaun Fleming, Marie Chanrion, Ana-Leticia Maragno, Laurence Kraus-Berthier, Seong Lin Khaw, Guillaume Lessene, David Huang, Andrew W. Roberts, MBBS, PhD, Olivier Geneste, Paul G Ekert, Ashley P Ng, Andrew H Wei, MBBS,PhD

Blood (2018) 132 (Supplement 1): 567.

https://doi.org/10.1182/blood-2018-99-114051

Published: 2018

Journal Articles

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Matthew S. Davids, MD, Andrew W. Roberts, MBBS, PhD, William G. Wierda, MD PhD, Kathryn Humphrey, Debbie J Alter, RN, BSN, Abdullah Masud, PhD, Eike C. Buss, MD, Maria E. Verdugo, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2018-99-117210

Published: 2018

Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2018-99-114048

Published: 2018

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Shuo Ma, MD PhD, Mary Ann Anderson, FRACP, FRCPA, MBBS, Michael Y. Choi, MD, Thomas J. Kipps, MD PhD, Kathryn Humphrey, Abdullah Masud, PhD, Ruby Nandam, RN, MSN, Su Young Kim, MD PhD, Maria E. Verdugo, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): 183.

https://doi.org/10.1182/blood-2018-183

Published: 2018

NARROW

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only